Klajdi, our CEO at Luminary Group, will be attending the World Drug Safety Congress Europe from 09-10 October. If you'd like to grab 5-10 minutes with Klajdi to discuss potential collaborations or share insights, feel free to reach out and connect. It’s a great opportunity to explore new ideas and strengthen relationships in the industry. Luminary Group has positioned itself as a leader in the consulting space, specializing in placing top executives and offering tailored commercial, operational, and outsourcing solutions for pharmaceutical companies in niche areas such as pharmacovigilance and regulatory affairs across Europe, the USA, and APAC. We are excited to meet with our industry partners and peers at the event. Looking forward to seeing you all there! #WDSC #pharmacovigilance #pharma #regulatory #compliance #pv #lifescience #healthcare #consulting #amsterdam #netherlands #worlddrugsafetyeurope #worlddrugsafety
Luminary Group
Business Consulting and Services
Global Life Sciences Consultancy.
About us
Luminary Group is a international business consultancy focused on the life sciences and pharmaceutical sectors. Headquartered at St Magnus House, 3 Lower Thames Street, Central London, EC3R 6HD, we deliver comprehensive services in three key areas. Luminary Executive: Specializing in C-suite to Director-level appointments, we identify top talent for positions including Chairman, Board members, CEO, CCO, COO, AVP to Director level. Luminary Staffing: We provide both temporary and permanent staffing solutions tailored to meet the commercial, project management, medical, biometrics, software and operational needs of our clients. Luminary Consulting: Offering high-quality services in medical writing, regulatory affairs, quality assurance, pharmacovigilance, and data science for the medical and pharmaceutical industries. We also provide strategic partnerships to accelerate growth through Recruitment Process Outsourcing (RPO) and Functional Service Provider (FSP) services. Lastly, our advisory services assist in data partnerships, leveraging our extensive network of leading RWE, RWD, and AI enterprises across the US and Europe, and provide guidance for business collaborations with biotechnology firms and navigating mergers and acquisitions. Our expertise includes Real World Evidence (RWE), eClinical solutions, Artificial Intelligence (AI), Biotechnology, Consulting, and Medical Devices. Operating globally with a presence in the USA, Europe, APAC, and the Middle East, we take pride in our exclusive talent pool, ranging from C-Suite to Managerial levels, and our partnerships with returning clients and candidates. Our collaborations extend across a diverse range of companies, from corporate giants to innovative start-ups. For more information, please visit our website: www.luminarygroup.co.uk.
- Website
-
www.luminarygroup.co.uk
External link for Luminary Group
- Industry
- Business Consulting and Services
- Company size
- 11-50 employees
- Headquarters
- City of London
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Executive Search, Headhunting, Consulting, Life Sciences, Pharmacovigilence, Regulatory Affairs, CMC, Biotechnology, Diagnostics, CRO, Clinical Trials, Cell & Gene Therapy, Machine Learning, Real World Evidence, Real World Data, eClinical, eCOA, RPO, FSP, Corporate Development, Partnerships, Data Partnerships, RWE, RWD, and Artificial Intelligence
Locations
-
Primary
City of London , GB
-
4th St N, STE 300
7901
St. Petersburg, FL , 33702, US
Employees at Luminary Group
Updates
-
𝗛𝗢𝗣𝗢 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝘄𝗶𝗻𝘀 𝘂𝗽 𝘁𝗼 $𝟮𝟮𝟲𝗠 𝗕𝗔𝗥𝗗𝗔 𝗰𝗼𝗻𝘁𝗿𝗮𝗰𝘁 𝗳𝗼𝗿 𝗵𝗲𝗮𝘃𝘆 𝗺𝗲𝘁𝗮𝗹 𝗽𝗼𝗶𝘀𝗼𝗻𝗶𝗻𝗴 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 HOPO Therapeutics scored a government contract for up to $226 million to develop an oral countermeasure against radiological threats and heavy metal poisoning. The funding …Julian Rees https://lnkd.in/g9M6S77r
-
𝗔𝗯𝗯𝗩𝗶𝗲 𝗺𝗮𝗸𝗲𝘀 $𝟭.𝟰𝗕 𝗮𝗰𝗾𝘂𝗶𝘀𝗶𝘁𝗶𝗼𝗻 𝗼𝗳 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿'𝘀 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 AbbVie said Monday it will pay $1.4 billion in cash to buy a Phase 1 Alzheimer’s and … https://lnkd.in/d7mt526k
AbbVie makes $1.4B acquisition of Alzheimer's biotech
endpts.com
-
𝗡𝗼𝘃𝗮𝗿𝘁𝗶𝘀 𝗽𝗮𝘆𝘀 𝗠𝗼𝗻𝘁𝗲 𝗥𝗼𝘀𝗮 $𝟭𝟱𝟬𝗠 𝗳𝗼𝗿 𝗣𝗵𝗮𝘀𝗲 𝟭 𝗱𝗿𝘂𝗴 𝗶𝗻 𝗹𝗮𝘁𝗲𝘀𝘁 𝗲𝗻𝗱𝗼𝗿𝘀𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗴𝗹𝘂𝗲𝘀 Novartis is getting a hold of one of Monte Rosa Therapeutics clinical-stage molecular glues, and it’s putting more than $2.2 billion on the table…Markus Warmuth https://lnkd.in/d3UP2ARD
Novartis pays Monte Rosa $150M for Phase 1 drug in latest endorsement of molecular glues
endpts.com
-
𝗥𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 𝗯𝗿𝗲𝗮𝗸𝘀 𝗴𝗿𝗼𝘂𝗻𝗱 𝗶𝗻 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗶𝗻𝗴 𝗽𝗮𝗻𝗰𝗿𝗲𝗮𝘁𝗶𝗰 𝗰𝗮𝗻𝗰𝗲𝗿 𝘄𝗶𝘁𝗵 𝘁𝘄𝗼 𝗥𝗔𝗦 𝗱𝗿𝘂𝗴𝘀 In an interview Friday, Revolution Medicines CEO Mark Goldsmith, M.D. who says he prefers to understate rather than exaggerate, floated a lofty goal: cure pancreatic cancer … https://lnkd.in/dnqXp_pi
Revolution Medicines breaks ground in challenging pancreatic cancer with two RAS drugs
endpts.com
-
𝗕𝗿𝗶𝘀𝘁𝗼𝗹 𝗠𝘆𝗲𝗿𝘀, 𝗜𝗱𝗲𝗮𝘆𝗮 𝘁𝗼𝘂𝘁 𝗱𝗮𝘁𝗮 𝗶𝗻 𝘀𝗼𝗹𝗶𝗱 𝘁𝘂𝗺𝗼𝗿𝘀 𝘄𝗶𝘁𝗵 𝗰𝗲𝗿𝘁𝗮𝗶𝗻 𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗺𝘂𝘁𝗮𝘁𝗶𝗼𝗻𝘀 Bristol Myers Squibb and IDEAYA Biosciences both released detailed snapshots of early-stage data for cancer drugs targeting solid tumors with a certain mutation known as … https://lnkd.in/dfSGXrUk
Bristol Myers, Ideaya tout data in solid tumors with certain genetic mutations
endpts.com
-
𝗦𝗲𝗽𝘁𝗲𝗿𝗻𝗮 𝗯𝗮𝗴𝘀 $𝟮𝟴𝟴𝗠 𝘂𝗽𝘀𝗶𝘇𝗲𝗱 𝗜𝗣𝗢 𝗳𝗼𝗿 𝗚𝗣𝗖𝗥 𝗱𝗿𝘂𝗴𝘀 Nascent clinical biotech Septerna added to the slight uptick in IPO fervor this fall with its $288 million Nasdaq listing on Friday. Investors seemed enthused … https://lnkd.in/de-JNCXA
Septerna bags $288M upsized IPO for GPCR drugs
endpts.com
-
𝗦𝗮𝗻𝗼𝗳𝗶 𝗯𝗮𝗰𝗸𝘀 𝗳𝗶𝗯𝗿𝗼𝘀𝗶𝘀 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗔𝗴𝗼𝗺𝗮𝗯 𝗮𝘀 𝗶𝘁 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟴𝟵𝗠 𝗦𝗲𝗿𝗶𝗲𝘀 𝗗 Agomab Therapeutics is benefiting from Sanofi's push to become an immunology powerhouse. The Antwerp-based biotech said Friday that the French drug giant and Invus are … Tim Knotnerus https://lnkd.in/dJG6dPKs
Sanofi backs fibrosis biotech Agomab as it raises $89M Series D
endpts.com
-
𝗥𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝘀𝘁𝗮𝗿𝘁𝘂𝗽𝘀 𝘀𝘁𝗮𝘆 𝗵𝗼𝘁 𝗮𝘀 𝗔𝗹𝗽𝗵𝗮-𝟵 𝗯𝗮𝗴𝘀 $𝟭𝟳𝟱𝗠 𝗦𝗲𝗿𝗶𝗲𝘀 𝗖 Another private radiopharmaceutical biotech has raised big money. Alpha-9 Oncology revealed on Wednesday that it’s put together a $175 million Series …David Hirsch https://lnkd.in/dnmEJJ_y
Radiopharma startups stay hot as Alpha-9 bags $175M Series C
endpts.com
-
𝗨𝗻𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 𝗼𝗳 𝗧𝗼𝗿𝗼𝗻𝘁𝗼 𝘀𝗽𝗶𝗻𝗼𝘂𝘁 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟱𝟯.𝟱𝗠 𝘁𝗼 𝗰𝗿𝗲𝗮𝘁𝗲 𝗻𝗲𝘄 𝗼𝗯𝗲𝘀𝗶𝘁𝘆 𝗱𝗿𝘂𝗴𝘀 𝘄𝗶𝘁𝗵 𝗔𝗜 A fusion of this year’s buzziest biotech trends — artificial intelligence and obesity drugs — is the focus of a new startup backed with $53.5 million from …Fable Therapeutics ,Geoff MacKay https://lnkd.in/dCsXkQ6Y
Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI
endpts.com